About Us

food allergy desensitization

Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy.

Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and stabilize allergenic proteins, representing a new therapeutic approach for the treatment of peanut and other food allergies.

Conducting allergy immunotherapy via teeth brushing is referred to as oral mucosal immunotherapy (OMIT). OMIT delivers allergenic proteins to the areas of the oral cavity, potentially driving the immune system toward tolerance without ingestion of the allergen. OMIT may address a significant health care need in the industrialized world, where the spread of food allergies has been characterized as an “epidemic.”

Intrommune’s mission is to develop safe, effective, and easy-to-use health solutions for individuals suffering with food allergy so that they and their loved ones can live their lives without fear.

Company Leadership


Michael Nelson

Michael Nelson, JD

Chief Executive Officer

Stuart Loesch

Stuart Loesch


Alain Van Loo

Alain Van Loo

Chief Operating Officer

Dr Berger

William Berger, MD, MBA

Head of Medical Affairs

Nandini Murthy

Head of Regulatory


Wendy Perrow, MBA

Head of Innovation

Ray Forsland

Ray Forslund Ph. D, MBA

Head of Chemistry, Manufacturing and Controls

Chris Schuster

Christopher R. Schuster, MBA

Chief Financial Officer

News & Resources

Want to learn more about Intrommune and our OMIT technology?
oral allergy desensitization
food immunotherapy
new treatment for food allergies
oit allergy therapy